

## **Santen Strengthens Global Product Supply Base with Completion of Third Building on Site of Shiga Product Supply Center**

October 26, 2022, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter Santen) held a ceremony today to mark the completion of its third building on the premises of the Shiga Product Supply Center (hereinafter Shiga PSC).

In anticipation of Santen's future business growth and product diversification in the global market, and as an initiative to implement the strategies of the medium-term management plan (MTP2025), a third building has been newly constructed to improve productivity by more than 30% through further automation and secure production capacity for a stable supply of products. Santen has operations in the Noto Plant (Ishikawa Prefecture) and the current Shiga PSC in Japan, which manufacture ophthalmic solutions. With this building in operation, annual production capacity for ophthalmic solutions at Shiga PSC will approximately double to 170 million units (based on 5mL units) at initial operation, allowing Santen to meet increasing global demand. Santen is also working to protect the global environment through resource conservation and reduction of environmental impact, through such measures as shifting to low-carbon energy sources, making effective use of water resources, and switching to biomass plastic containers.

In addition to global population growth and aging, eye diseases caused by lifestyle-related diseases are expected to continue to increase, and the global demand for ophthalmic solutions is expected to increase accordingly. In addition, Santen believes that its mission as a specialized company in ophthalmology is to continue to provide patients with a stable product supply, even under various unforeseen circumstances.

As a company specializing in eye health, Santen aspires to create a world where each person can live their happiest life through the best vision experience. Santen continues to help reduce the loss of social and economic opportunities resulting from eye conditions by providing solutions in ophthalmology, by encouraging people to pursue eye wellness, and by creating a society that is inclusive in which people with and without visual impairment interact easily and play equal roles.

## ■ Overview of Shiga PSC Third Building

Location	348-3, Suwa, Oaza-Shimote, Taga-cho, Inukami-gun, Shiga
Floor area	23,974m <sup>2</sup>
Structures	Formulation building #3 (including automated warehouse), recycling building
Start of construction	February 2021
Completion	August 2022
Production capacity	Maximum of 6 production lines Annual output of approximately 170 million bottles (based on 5mL units) at initial operation
Commission date	Production scheduled to start progressively from FY2023



Shiga PSC Third Building (Center)



Left: Takeshi Ito, President & CEO  
Right: Akira Kurokawa, Chairman

## **About Santen**

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator,” Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en/>).

## **Contact**

Corporate Communications

Santen Pharmaceutical Co., Ltd.

E-mail: [communication@santen.com](mailto:communication@santen.com)